Lidocaine-Liqvo with epinephrine solution for injection

Country: Armenia

Language: English

Source: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Active ingredient:

lidocaine (lidocaine hydrochloride), epinephrine

Available from:

Liqvor CJSC

ATC code:

N01BB52

INN (International Name):

lidocaine (lidocaine hydrochloride), epinephrine

Dosage:

10mg/ml+ 0,01mg/ml

Pharmaceutical form:

solution for injection

Units in package:

(1) and (10) glass vial 20ml

Prescription type:

Prescription

Authorization status:

Registered

Authorization date:

2018-07-11

Patient Information leaflet

INSTRUCTIONS FOR MEDICAL USE
LIDOCAINE-LIQVO WITH EPINEPHRINE
1 % and 2 % solution for injection
TRADE NAME: Lidocaine-Liqvo with epinephrine
INTERNATIONAL NONPROPRIETARY NAME: Lidocaine, Epinephrine.
PHARMACEUTICAL FORM: Solution for injection.
STRENGTH: 1 % and 2 % with epinephrine 1:100000
COMPOSITION: _ active ingredients_: lidocaine hydrochloride – 10.0
mg or 20.0 mg, epinephrine
hydrotartrate equivalent to epinephrine – 0.01 mg; _inactive
ingredients_: sodium chloride – 7.0 mg,
sodium metabisulfite – 0.5 mg, citric acid – 0.2 mg, benzalkonium
chloride – 0.05 mg, water for
injection – up to 1.0 ml.
DESCRIPTION: Clear, colorless or slightly yellowish solution.
PHARMACOTHERAPEUTICAL GROUP: Local anesthetic.
CODE ATC: N01BB52
PHARMACOLOGICAL EFFECT
_PHARMACODYNAMICS _
Lidocaine is a local anaesthetic of the amide type. It causes all
types of local anesthesia: terminal,
infiltration, conduction. The local anesthetic action consists in
neuronal membrane stabilization by
reducing its penetration for sodium ions, which prevents action
potential occurrence and impulse
conduction. It rapidly hydrolyzes in a slightly alkaline media of
tissues and after a short latent
period acts within 60-90 minutes. Anesthetic activity decreases with
tissue acidosis.
Epinephrine - adrenoceptor agonist, constricts blood vessels and
prolongs lidocaine action.
_PHARMACOKINETICS _
Lidocaine is readily absorbed from the gastrointestinal tract, from
mucous membranes and through
damaged skin also in case of intramuscular administration.
The elimination half-life is 2 hours.
Lidocaine is metabolized in liver with formation of two
pharmacologically active metabolites. It_ _
eliminates with urine: approximately 90% of dose is excreted in the
form of metabolites and less
than 10% - unchanged.
Lidocaine crosses the blood-brain and placental barriers.
_ _
_ _
INDICATIONS FOR USE
All types of local anesthesia (infiltration and conduction anesthesia,
peripheral nerve blocks) in
dentistry, ophthalmology, otorhinolaryngology, obstetrics

Summary of Product characteristics

CYM.I$
APHA
fr
XAFAKTNFI.{.C
T}.I
KA
fi
A
KAPCT:BAHI{
O
I-
O
.
: :
. :
.
NPHIIAPAT'A
JIHIIOKAI{I{-fl14KBO
c
slrI{He{rpr'rnou
p
A
c"rB0
p
fl
.rln
lt rrr,
er
rcqHil
I.
Konrmepqecgoe
Hatr1r,rerronRnire
Hp€,lrftpnra:
-llmgclxalrul-Jl.Hmuo
c SIlt{ttetfpr'tHoir,t
Mexgynapognoe
rdar{M€HoBaHrre
t}IirIIBIIsro
BeIIIecTBa;
JlLtlIoKaHH.
J[
r"tAo
xitl.t
FI
a r]"Ir:tp
oxJlolltlJt
3 ni,rnedlp
pi
ir fr
rl,lgpol:ap
ar
(n
ilepecrlere
Ha
rnnne$pr.tn)
Bcno.'ttoza
m
€..it
bt-t
d
e
ge
u{e(
tn6fr
;
FIarpr'u
xitopl'Iit
Harpr'tn
u
era6ltcytn
r'$llr
Kltc;lttl'ra;r,ltH,:tlllueu
::
:
E exsalxonl.Tfl
xiropl,Ir
B ojla
riu{
I'Ir-I"l;ercuutl
3.
@apncauerTll,Hecliafi
rpapma:
paetnop
finx
I :100000
:
4. Kn
HHI{(IecKIIe
xa
pa
K r e p l t c r l { K H
4,1
flara3aullff
K
npltmeilenlllo
Ilce
eggbr
[4ecrHofr
aHscr:e3r,tn
(lrnfturrurpirqnonFlfl$,
npono.{FlldKoBflfi
al{ecre3l4s}
6lorajta
ilepFr$epuuecnlrx ,
r{epBors)
n
cloturaroilorl{Fl,
odir:aur,turoror}lr{.
o.ropFi-IoJrapr"tHr'ojlor"r.i4.
aKyr.rJellcTBe,
Il{FIeKOJtO[rdl4.
Xl,Ipypr]lt{-
JIepMA'r0,rlol"{1'1.
I
rnrane.clpHH.
2,
Ksnn*recr*e*Huft
u **,-il***ennnrfi
oo***
.u$rtt
fl
it
;
t
d'r€fffd
$6'
'LP/8
il,
ffi;*-"'
""r
vY+!
ws
f
io
r,
r-'i
il
i,
ii
{
r,;
!Jb4,'r,/
ad
f {
10.0:Lrr
I'lnll
20,0 ur
-
0 , 0 1 i v l r
7"0 ir,tr
:
-
0oS
n$r
,
,,
-
0o?
ntr
'
-0,05
nrr
:
-
Ao
I rln.
,*iur,**Hlu,lT-
I X
u 2"/o
c 3lr
l'lHe$pnnom
B:pgc.llt
rM Fr
Ae1rr\{
c'rapilte
l2 .i.re"r
ilorra3auo
ilpt"t\tsltenl'le
lu/o
tt 2 %
pacrl}oiloB
JtLtJloKtl{I1t[;
jlerriM
[]
It03pa,f're
crttl]iile
.l
lo.na
{to
t?
,rler
7o/r,
pacrBCIpa
4.2.
Cnoco6
np'MerreH'n
[r
Ao3l,r
r*,ii
i"
i:
ig!c{I/p6'
il
{'
At}f€"
l*err*oro
rnu'*t,ur.
ii
i'Il-'iiit;
iiir'l
'
/16
%a
;/
!
:
n i
"
"
;
r
i
i
Pexpl;vt.q03tlpoBar-tptfi
)'c'rarJilBilttBilloT
r.rFrllHBI,TiIyarbll,o"
B
3i1B!ICIdN'lOCT'I'I
OT
nona3ar{nir.
nrutlri.FttscKoii
u"r.:r'r,au}.rr{
pr
r{ciloJlbs),eur:tYt
$erapcrneituofi
$optutur.
liperrapnl
cJreJweir
BBo;1l,t'lr,
Me.ilitelrr,Io.
B
rI[tFrN'l€ll.blUeilt
ttoHHefflip{}l{l{l'I
r{
Har.ri\,rer{bmepi
jlo3e.
,lrarogeu
'rpe6yeirtr,Il:i
rclrQexr.
I